Tumor Testing May Be Increasingly Useful in Ovarian Cancer

May 8, 2023 3:00 pm

Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.

Among 1,092 patients with ovarian cancer, 27.5% underwent next-generation sequencing; 96.1% had one or more genetic alteration; 25.9% had an alteration that aligned with targeted treatment

In an

Read more

Fred Hutch study highlights racial disparities in ovarian cancer risk for women

May 4, 2023 2:48 pm

Researchers examined risks for Black and white women with endometriosis and fibroids to understand how common medical interventions for those conditions modified the outcomes

SEATTLE, WA — May 4, 2023 — A new Fred Hutchinson Cancer Center study in the

Read more

Mirvetuximab Soravtansine Continues to Outperform Chemo in FRα-High Ovarian Cancer

May 3, 2023 9:19 am

by Jordan Sava

Impressive efficacy data and consistent safety data continue to be seen with mirvetuximab soravtansine for the treatment of patients with platinum-resistant ovarian cancer, according to data from the confirmatory MIRASOL trial.

Mirvetuximab sorvtansine-gynx (Elahere) demonstrated statistically significant

Read more

Exome sequencing identifies cancer predisposition-gene carriers screening guidelines miss

April 19, 2023 12:55 pm

by Jennifer Southall

Whole-exome sequencing identified carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome who, under current guidelines, would not have qualified for genetic testing, according to study results.

The findings, presented at American Association … Read more

Dual Inhibition of PARP and ATR Feasible, Early Trials Suggest

April 19, 2023 12:40 pm

by Leah Lawrence

Early-phase trials testing the safety and efficacy of PARP inhibition plus ataxia telangiectasia- and Rad3-related kinase (ATR) inhibition in biomarker-selected patients show intriguing results, researchers reported at the AACR Annual Meeting 2023.

“ATR inhibition prevents recovery from … Read more

Preclinical Study Reveals New Target for Drug-Resistant Ovarian Cancer

April 18, 2023 1:04 pm

There are currently three antibody drug conjugates (ADC) targeting B7-H4 being tested in clinical trials: AZD8205 (NCT05123482), SGN-B7-H4V (NCT05194072) and XMT-1660 (NCT05377996). You can use Clearity’s clinical trial finder to find more information about these trials.

As part of the … Read more

SWOG investigators report results from DART clinical trial of immunotherapy combination for rare gynecologic cancers

April 18, 2023 10:20 am

Reviewed by Emily Henderson, B.Sc

Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare … Read more

Lifirafenib Plus Mirdametinib Shows Tolerable Safety in BRAF/KRAS Mutant Advanced Solid Tumors

April 17, 2023 12:29 pm

by Nichole Tucker

The success of BRAF/MEK combinations has led to the discovery of safety and preliminary activity with an investigational pan-RAF/MEK combination.

The investigational combination of lifirafenib (BGB-283) and mirdametinib (PD-0325901) has shown a favorable safety profile, as well Read more

Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations

April 5, 2023 4:55 pm

by Nichole Tucker

The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting Read more

1 in 4 patients at gynecologic oncology clinic lack adequate cancer health literacy

March 29, 2023 9:55 am

by Matthew Shinkle

One of every four patients with a gynecologic oncology office visit had inadequate levels of cancer health literacy, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Researchers found racial and ethnic … Read more

CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer

March 27, 2023 9:52 am

by Charles Bankhead

TAMPA, Fla. — About a fourth of patients with recurrent low-grade serous ovarian cancer (LGSOC) obtained durable responses to the combination of CDK4/6 inhibitor ribociclib (Kisqali) and letrozole, a small single-arm trial showed.

Overall, 23% of 48 … Read more

Clinical Trial Participation Linked to Longer OS in Platinum-Resistant Ovarian Cancer

March 27, 2023 9:42 am

by Jessica Nye, PhD

Patients with platinum-resistant epithelial ovarian cancer may have better overall survival (OS) if they enroll on a clinical trial than if they receive standard care, according to study results presented at the 2023 SGO Annual Meeting … Read more

Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer

March 27, 2023 9:13 am

by Devin McLaughlin

Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Researchers observed favorable surgical outcomes — even … Read more

Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer

March 27, 2023 9:11 am

by Jason Harris

Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1Read more

Adding HIPEC to Cytoreductive Surgery Does Not Impact HRQOL in Ovarian Cancer

March 25, 2023 9:47 am

by Hayley Virgil

Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.

Combining hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery

Read more

Chemotherapy-resistant ovarian cancer cells protect their neighbors, shows study

March 3, 2023 10:10 am

by University of Pittsburgh

Certain chemotherapy-resistant ovarian cancer cells protect neighboring cancer cells by sending signals that induce resistance, according to a new study from University of Pittsburgh and UPMC researchers that may help explain why ovarian cancer patients respond … Read more

Tailored Phone Calls Increased Rate of Genetic Testing, Counseling for Hereditary Cancer Risk

March 2, 2023 9:44 am

by Alison Kanski

NEW YORK – Personalized phone discussions about genetic risk assessment increased the number of breast and ovarian cancer patients who got genetic testing or discussed their risk with a genetic counselor, a study from Rutgers Cancer Institute … Read more

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

March 1, 2023 9:26 am

by Justin Jackson

An international team led by researchers from MacCallum Cancer Center in Melbourne, Australia, examined 391 tumor tissues from about 270 multisite autopsy samples collected from 15 individuals with end-stage high-grade serous ovarian cancer (HGSC). All of the … Read more

Ovarian Cancer in Black and African American Communities

February 3, 2023 3:10 pm

Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed Read more

OCRA Issues Consensus Statement Calling for Consideration of Fallopian Tube Removal to Prevent Ovarian Cancer

February 3, 2023 2:16 pm

by Jo Cavallo

The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has shown that general population screening did not significantly reduce ovarian and tubal cancer deaths, and the researchers concluded that such screening cannot be recommended. The findings from … Read more